These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11340577

  • 1. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.
    Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N.
    Int J Cancer; 2001 Jun 01; 92(5):712-7. PubMed ID: 11340577
    [Abstract] [Full Text] [Related]

  • 2. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
    Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N.
    Int J Cancer; 1998 Oct 29; 78(3):366-71. PubMed ID: 9766573
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.
    Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takiguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N.
    Cancer Lett; 2000 Feb 28; 149(1-2):195-202. PubMed ID: 10737724
    [Abstract] [Full Text] [Related]

  • 5. Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice.
    Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki N.
    J Urol; 2002 Sep 28; 168(3):1182-7. PubMed ID: 12187264
    [Abstract] [Full Text] [Related]

  • 6. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
    Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N.
    Gene Ther; 1994 Nov 28; 1(6):403-7. PubMed ID: 7584106
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
    Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF.
    Cancer Gene Ther; 2000 Dec 28; 7(12):1575-80. PubMed ID: 11228536
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
    Irie A, Anderegg B, Kashani-Sabet M, Ohkawa T, Suzuki T, Halks-Miller M, Curiel DT, Scanlon KJ.
    Antisense Nucleic Acid Drug Dev; 1999 Aug 28; 9(4):341-9. PubMed ID: 10463078
    [Abstract] [Full Text] [Related]

  • 12. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo.
    Mühlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC.
    Circ Res; 1995 Dec 28; 77(6):1077-86. PubMed ID: 7586219
    [Abstract] [Full Text] [Related]

  • 13. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer.
    Sutton MA, Freund CT, Berkman SA, Dang TD, Kattan MW, Wheeler TM, Rowley DR, Lerner SP.
    Mol Ther; 2000 Sep 28; 2(3):211-7. PubMed ID: 10985951
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo.
    Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC.
    Int J Cancer; 1995 Nov 27; 63(5):673-9. PubMed ID: 7591284
    [Abstract] [Full Text] [Related]

  • 16. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model.
    Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T, Ikeda S.
    Cancer Gene Ther; 2004 Jun 27; 11(6):431-40. PubMed ID: 15118756
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.